Table of Contents
ISRN Pharmacology
Volume 2013 (2013), Article ID 146579, 7 pages
http://dx.doi.org/10.1155/2013/146579
Research Article

Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients

1Departments of Pharmacy and Clinical Pharmacy, Hamad General Hospital, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar
2Departments of Medicine and Endocrinology, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar
3Department of Medical Statistics and Epidemiology, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar
4Departments of Public Health and Medical Education, Weill Cornell Medical College in Qatar, P.O. Box 3050, Doha, Qatar
5Department of Evidence for Population Health Unit, School of Epidemiology and Health Sciences, The University of Manchester, Manchester, UK
6Pediatric Intensive Care Unit, Department of Pediatrics, Hamad Medical Corporation, P.O. Box 3050, Doha, Qatar

Received 6 December 2012; Accepted 3 January 2013

Academic Editors: T. Kumai and T. B. Vree

Copyright © 2013 Lolwa Barakat et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objectives. To investigate the efficacy and the safety of the three most commonly prescribed statins (rosuvastatin, atorvastatin, and pravastatin) for managing dyslipidemia among diabetic patients in Qatar. Subjects and Methods. This retrospective observational population-based study included 350 consecutive diabetes patients who were diagnosed with dyslipidemia and prescribed any of the indicated statins between September 2005 and September 2009. Data was collected by review of the Pharmacy Database, the Electronic Medical Records Database (EMR viewer), and the Patient's Medical Records. Comparisons of lipid profile measurements at baseline and at first- and second-year intervals were taken. Results. Rosuvastatin (10 mg) was the most effective at reducing LDL-C (29.03%). Atorvastatin reduced LDL-C the most at a dose of 40 mg (22.8%), and pravastatin reduced LDL-C the most at a dose of 20 mg (20.3%). All three statins were safe in relation to muscular and hepatic functions. In relation to renal function, atorvastatin was the safest statin as it resulted in the least number of patients at the end of 2 years of treatment with the new onset of microalbuminuria (10.9%) followed by rosuvastatin (14.3%) and then pravastatin (26.6%). Conclusion. In the Qatari context, the most effective statin at reducing LDL-C was rosuvastatin 10 mg. Atorvastatin was the safest statin in relation to renal function. Future large-scale prospective studies are needed to confirm these results.